Tenapanor Lowers Serum Phosphate in Dialysis Patients
A new study reveals tenapanor successfully reduces serum phosphate levels in patients undergoing dialysis treatment.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Do you prefer to use one medication at a time or combine multiple treatments for health?
A retrospective study of 1,477 dialysis patients found that tenapanor significantly reduced serum phosphate levels over a six-month period. These findings were recently presented at the ASN Kidney Week 2026 conference in Denver.
Why it matters
Managing phosphate levels is critical for dialysis patients, and this study helps clarify the real-world effectiveness of tenapanor when used alongside different background binder treatments. Understanding these outcomes assists clinicians in optimizing long-term therapeutic strategies.
The study observed adjusted mean serum phosphate reductions between 0.80 and 1.55 mg/dL. Patients showed a 16% to 41% probability of reaching target phosphate levels, while 60% to 70% remained on the 30 mg twice-daily regimen for 180 days.
The players
American Society of Nephrology
This professional organization hosts the annual ASN Kidney Week conference, which serves as a global forum for the latest clinical research in nephrology.
Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and medical devices.
The details
Researchers analyzed electronic health records to evaluate the drug, which blocks phosphate absorption through the paracellular pathway. While effective, clinical trials previously identified diarrhea as a side effect for 43% to 53% of patients, with 5% experiencing severe cases.
Timeline
The FDA approved tenapanor in October 2023.
Patients in the study initiated tenapanor between November 2023 and June 2025.
Study results were presented on October 21-25, 2026, at ASN Kidney Week 2026.
Health Landscape
This study adds to the growing body of evidence presented at the ASN Kidney Week conference regarding non-traditional phosphate-lowering therapies. It highlights an evolution in renal care, moving toward targeted pathways beyond legacy calcium-based binders.
Patients prescribed this 30 mg twice-daily treatment should monitor for gastrointestinal side effects, which affected up to 53% of clinical trial participants. Consulting with a nephrologist remains essential to determine how this therapy fits into an individual's specific dialysis regimen.
The takeaway
Real-world evidence supports the use of tenapanor in managing phosphate levels for dialysis patients, though side effect profiles require careful oversight. Clinicians and patients should discuss the balance between phosphate reduction and digestive tolerance when considering this medication.
Further reading
For more information on clinical approaches to mineral metabolism, see the Nutrition section.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you prefer to use one medication at a time or combine multiple treatments for health?
